Our top pick for
Building a portfolio
Ionis Pharmaceuticals, Inc is a biotechnology business based in the US. Ionis Pharmaceuticals shares (IONS) are listed on the NASDAQ and all prices are listed in US Dollars. Ionis Pharmaceuticals employs 757 staff and has a trailing 12-month revenue of around USD$729.3 million.
|52-week range||USD$41.42 - USD$64.37|
|50-day moving average||USD$50.9324|
|200-day moving average||USD$52.3122|
|Wall St. target price||USD$56.94|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.518|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ionis Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 101x. In other words, Ionis Pharmaceuticals shares trade at around 101x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ionis Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$128.6 million.
The EBITDA is a measure of a Ionis Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$729.3 million|
|Gross profit TTM||USD$182.2 million|
|Return on assets TTM||-3.16%|
|Return on equity TTM||-38.51%|
|Market capitalisation||USD$6 billion|
TTM: trailing 12 months
There are currently 8.6 million Ionis Pharmaceuticals shares held short by investors – that's known as Ionis Pharmaceuticals's "short interest". This figure is 1% up from 8.5 million last month.
There are a few different ways that this level of interest in shorting Ionis Pharmaceuticals shares can be evaluated.
Ionis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ionis Pharmaceuticals shares currently shorted divided by the average quantity of Ionis Pharmaceuticals shares traded daily (recently around 876870.37793667). Ionis Pharmaceuticals's SIR currently stands at 9.79. In other words for every 100,000 Ionis Pharmaceuticals shares traded daily on the market, roughly 9790 shares are currently held short.
However Ionis Pharmaceuticals's short interest can also be evaluated against the total number of Ionis Pharmaceuticals shares, or, against the total number of tradable Ionis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ionis Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ionis Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0724% of the tradable shares (for every 100,000 tradable Ionis Pharmaceuticals shares, roughly 72 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ionis Pharmaceuticals.
Find out more about how you can short Ionis Pharmaceuticals stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 36.64
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 12/31/2018) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.18/100
Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 26.17/100
Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.29/100
Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
|Total ESG score||36.64|
|Total ESG percentile||62.18|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $41.42 up to $64.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 1.0976. This would suggest that Ionis Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.